Health UCB Reports Positive Phase 3 Results for Fenfluramine in CDKL5 Disorder UCB, a global biopharmaceutical company, revealed promising results from its GEMZ phase 3 study of fenfluramine for treating seizures associated with CDKL5 Deficiency Disorder... Editorial2 days ago